comparemela.com
  1. Home
  2. Live Updates
  3. HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression : comparemela.com

HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

Related Keywords

Germany ,Switzerland ,South Africa ,Munich ,Bayern ,Pratteln ,Switzerland General ,Australia ,Schopfheim ,Baden Wüberg ,Swiss ,German ,Develco Pharma ,Anne Donohoe ,Sophia Bashford ,Hans Eriksson ,Ketabon Program ,Holding Gmb ,Brain Health ,Topline Results Expected ,Treatment Resistant Depression ,Chief Medical Officer ,Depression Rating Scale ,Major Depressive Disorder ,Middle East ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.